Curiously, PRAME could act as an oncogene or tumor suppressor gene in different cancer types, exerting its biological functions through the regulation of its downstream targets (p53, p21, Bcl-2, TRAIL, RAR, Hsp27, and S100A4); besides, PRAME has a pivot role in the immunotherapy response and may be an attractive target for immunotherapy [96,97,98,99]. The gene discussed is BCL2; the disease is cancer.